Takeda Pharmaceutical Stock Revenue
| TKDA Stock | EUR 12.80 0.20 1.54% |
Takeda Pharmaceutical fundamentals help investors to digest information that contributes to Takeda Pharmaceutical's financial success or failures. It also enables traders to predict the movement of Takeda Stock. The fundamental analysis module provides a way to measure Takeda Pharmaceutical's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Takeda Pharmaceutical stock.
Takeda |
Takeda Pharmaceutical Company Revenue Analysis
Takeda Pharmaceutical's Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Current Takeda Pharmaceutical Revenue | 3.57 T |
Most of Takeda Pharmaceutical's fundamental indicators, such as Revenue, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Takeda Pharmaceutical is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
| Competition |
Based on the latest financial disclosure, Takeda Pharmaceutical reported 3.57 T of revenue. This is much higher than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—Specialty & Generic industry. The revenue for all Germany stocks is significantly lower than that of the firm.
Takeda Revenue Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Takeda Pharmaceutical's direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Takeda Pharmaceutical could also be used in its relative valuation, which is a method of valuing Takeda Pharmaceutical by comparing valuation metrics of similar companies.Takeda Pharmaceutical is currently under evaluation in revenue category among its peers.
Takeda Fundamentals
| Return On Equity | 0.0477 | |||
| Return On Asset | 0.0247 | |||
| Profit Margin | 0.07 % | |||
| Operating Margin | 0.13 % | |||
| Current Valuation | 71.66 B | |||
| Shares Outstanding | 3.12 B | |||
| Shares Owned By Institutions | 2.23 % | |||
| Price To Earning | 29.55 X | |||
| Price To Book | 0.95 X | |||
| Price To Sales | 0.01 X | |||
| Revenue | 3.57 T | |||
| Gross Profit | 2.44 T | |||
| EBITDA | 1.05 T | |||
| Net Income | 230.06 B | |||
| Cash And Equivalents | 1000 B | |||
| Cash Per Share | 320.73 X | |||
| Total Debt | 4.14 T | |||
| Debt To Equity | 0.99 % | |||
| Current Ratio | 1.53 X | |||
| Book Value Per Share | 1,986 X | |||
| Cash Flow From Operations | 1.12 T | |||
| Earnings Per Share | 0.61 X | |||
| Price To Earnings To Growth | 0.57 X | |||
| Target Price | 20.28 | |||
| Number Of Employees | 47.35 K | |||
| Beta | 0.7 | |||
| Market Capitalization | 45.72 B | |||
| Total Asset | 13.18 T | |||
| Annual Yield | 0.04 % | |||
| Net Asset | 13.18 T | |||
| Last Dividend Paid | 180.0 |
About Takeda Pharmaceutical Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Takeda Pharmaceutical's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Takeda Pharmaceutical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Takeda Pharmaceutical based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Takeda Stock
Takeda Pharmaceutical financial ratios help investors to determine whether Takeda Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Takeda with respect to the benefits of owning Takeda Pharmaceutical security.